On October 3, 2023, Christopher Brooke resigned as Chief Operating Officer of Aytu BioPharma, Inc. (the ?Company?), effective October 13, 2023, to pursue another opportunity at a development-stage biotechnology company. Mr. Brooke?s resignation is not due to any outstanding issues with the Company or disagreements with respect to the Company?s operations, policies or practices, or the Company?s independent auditors. The Company does not intend to seek a replacement for the position of Chief Operating Officer given the Company?s wind down of manufacturing operations at its Grand Prairie, TX production facility and indefinite suspension of all pipeline research and development programs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.904 USD | +2.26% | +4.10% | +2.26% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.26% | 16.17M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer